Liquidia Corporation (LQDA)

Liquidia's stock has experienced significant positive momentum over the past six months, increasing by 158.06% from April 2, 2025, to April 1, 2026, and delivering a 186.2% return over the past year. Key events impacting the stock price include strong financial results and the successful launch of YUTREPIA, participation in investor conferences and presentations, and preliminary sales and corporate updates. There was also a disclosure of insider trading involving the sale of shares by the Chairman of the Board. The company faces ongoing legal uncertainties.

Liquidia reported that YUTREPIA accounted for more than 100% of the inhaled treprostinil market growth in Q4 2025, despite competitors reporting seasonality. This suggests that while the broader market for inhaled treprostinil might experience seasonality, Liquidia's strong launch momentum and product profile for YUTREPIA have allowed it to overcome or mitigate these seasonal effects, at least in the recent past.

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for respiratory and vascular diseases, particularly rare cardiopulmonary conditions and pulmonary hypertension (PH). Their proprietary PRINT® technology enables precise design and manufacturing of uniform drug particles to enhance drug delivery to the lungs. Liquidia's lead product is YUTREPIA™ (treprostinil) inhalation powder, indicated for adults with PAH and PH-ILD to improve exercise ability. They are also developing L606 and promote generic Treprostinil Injection for PAH through a profit-sharing agreement with Sandoz.

Liquidia Corporation is headquartered in Morrisville, North Carolina, United States. While its primary operations are based in the U.S., the company has expressed plans for global market expansion, particularly in regions with high unmet medical needs.

Liquidia's brand reputation has been significantly bolstered by the successful launch and rapid uptake of YUTREPIA, recognized as a top specialty drug launch. The company's ability to rapidly achieve profitability and its strong market share capture in the pulmonary hypertension market have positively impacted its reputation. The company's proprietary PRINT® technology is also a key aspect of its innovative reputation. However, ongoing legal uncertainties pose a potential risk to its reputation.

Liquidia Corporation's ownership is a mix of institutional, insider, and public/individual investors. Institutional investors hold approximately 47.02% to 57% of the company's stock, with major holders including Farallon Capital Management Llc and Caligan Partners LP. Insiders own approximately 21.80% of the company's stock, with significant individual owners including Paul Manning and CEO Roger Jeffs. The general public holds around 14% to 38% of the shares.